Several authors have proposed the use of HSD17B1 inhibitors for breast cancer, either as a single treatment, conceivably once resistance to aromatase inhibitors has arisen, or in combination with other treatments [46, 71, 72]. This evidence concerns the gene CYP19A1 and breast cancer.